Feds Endorse Fat-Blocking OTC Pill
Orlistat, a fat blocking pill has moved a step closer to federal approval.
An FDA advisory panel voted 11-3 late Monday to recommend that the regulatory agency approve the nonprescription form of orlistat, which Glaxo would market as Alli (pronounced “ally”). The agency is not bound by the recommendation but usually follows the advice of its expert panels.
